Indaptus Therapeutics completes safety, PK, biomarker data on Decoy20

Indaptus Therapeutics (INDP) announces compelling safety, pharmacokinetics, PK, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer, SITC, 2024 annual meeting. The data derive from two cohorts of Decoy20 single administration and one cohort (6 patients) of Decoy20 weekly administration in the Company’s ongoing Phase 1 clinical trial. The SITC conference is being held November 6-10, 2024 in Houston, Texas. The data presented demonstrated that Decoy20 administered intravenously once weekly mainly showed side effects that were classified as mild or moderate and transient in duration. Further, pharmacokinetic analysis confirmed that Decoy20 quickly disappeared from the bloodstream after administration, supporting the Company’s “pulse” approach. One patient in the trial who has squamous cell carcinoma of the head and neck with high levels of PD-L1, which is a protein that is associated with tumor response to certain immunotherapies, had “stable disease” – meaning the cancer had not progressed or worsened – at the time of their first imaging scan.